KOSDAQBiotech & Pharma109820

Genematrix

₩1,278▲ 0.16%2026-11-18 close
Market Cap
₩26.1B
Turnover
₩16,277,371
Volume
10K
Shares out.
20.4M
PER
—
PBR
1.5×
EPS
-₩53
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Export-led molecular diagnostics; quarterly profit still the test

Export growth has narrowed annual losses through 2025, but quarterly results swung back to a loss in the third quarter of 2026 after one profitable quarter, so sustained profitability is not yet established.

  1. 1

    Operating profit turned positive in the second quarter of 2026, but the third quarter returned to an operating loss of KRW 130 million.

  2. 2

    The 2025 operating loss narrowed to KRW 679 million from KRW 1.64 billion in 2024, and operating cash flow turned positive at KRW 1.29 billion.

  3. 3

    Exports are the growth engine: second-quarter 2026 export sales rose 96% year on year, and the company says more than 40% of total sales come from exports.

  4. 4

    The debt-to-equity ratio rose from 31.9% in 2022 to 56.1% in 2025, and total equity stood at KRW 17.5 billion at the end of 2025.

  5. 5

    The hepatitis A vaccine candidate GMAI-02 has entered a Phase 1 clinical trial agreement with Seoul National University Hospital, aiming at domestic supply of a vaccine now largely imported.

02

Business structure

Genematrix was founded in 2000 to develop pharmaceuticals and diagnostics through biotechnology and listed on KOSDAQ in 2009.

Its core is the NeoPlex product family, a multiplex molecular diagnostic line built on proprietary multiplex PCR technology that covers sexually transmitted infections (STI), human papillomavirus (HPV), respiratory infections (RI), tuberculosis and nontuberculous mycobacteria (TB/NTM), and gastrointestinal (GI) tests.

Product sales account for most of revenue, with smaller merchandise and other sales. The company says more than 40% of total sales come from NeoPlex exports. In the second quarter of 2026, HPV test sales rose 266% year on year, STI test sales rose 113%, and respiratory product sales rose 28%.

The line extends to blood chemistry tests and point-of-care testing products. In June 2026, its TB/NTM-5 detection kit received CE-IVDR listing in Europe.

In April 2026 the company signed a strategic memorandum with the in-vitro diagnostics firm Zybio, under which Zybio supplies extraction and pretreatment equipment while Genematrix distributes diagnostic products in target countries. The company positions NeoPlex's accuracy and multiplex performance as its competitive edge.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.6B-₩100M−4.2%
2025Q4₩2.9B-₩200M−6.7%
2026Q1₩2.5B-₩300M−13.0%
2026Q2₩2.9B₩400M13.5%
2026Q3₩2.5B-₩100M−5.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩11.2B-₩1.5B-₩8.1B−13.6%−33.5%31.9%
2023₩9.8B-₩2.5B-₩900M−26.0%−3.9%35.4%
2024₩10B-₩1.6B-₩3.7B−16.4%−19.5%48.0%
2025₩10.6B-₩700M-₩1.8B−6.4%−10.5%56.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 11.2 billion in 2022 to KRW 9.81 billion in 2023, a 12.5% decline, then rose to KRW 10 billion in 2024 (up 2.1%) and KRW 10.6 billion in 2025 (up 6.2%), so revenue has grown for two consecutive years from 2024 through 2025. 2022 was the largest year for revenue and 2023 the smallest.

The operating loss widened from KRW 1.52 billion in 2022 to KRW 2.55 billion in 2023, then narrowed to KRW 1.64 billion in 2024 and KRW 679 million in 2025. Operating margins were -13.6% in 2022, -26.0% in 2023, -16.4% in 2024 and -6.4% in 2025, and the company has reported losses in each year from 2022 through 2025.

The company attributed the 2025 improvement to higher overseas sales, lower selling and administrative expenses, and smaller valuation losses on financial assets at fair value through profit or loss.

Net loss attributable to controlling shareholders was KRW 8.11 billion in 2022, KRW 895 million in 2023, KRW 3.75 billion in 2024 and KRW 1.83 billion in 2025, and the total net loss was reported at the same amounts.

In 2024 the operating loss narrowed while the net loss widened, which points to non-operating items as a major factor, so the line-item breakdown in the annual report needs checking.

Operating cash flow was negative at KRW -1.02 billion in 2022, KRW -2.35 billion in 2023 and KRW -200 million in 2024, then turned positive at KRW 1.29 billion in 2025.

The debt-to-equity ratio rose from 31.9% in 2022 to 56.1% in 2025, with total equity of KRW 17.5 billion and total liabilities of KRW 9.8 billion at the end of 2025. Quarterly revenue ran between KRW 2.48 billion and KRW 2.91 billion across the last five quarters.

Operating results moved from losses of KRW 109 million in the third quarter of 2025 and KRW 191 million in the fourth quarter to losses of KRW 327 million in the first quarter of 2026, then an operating profit of KRW 393 million in the second quarter, and back to a KRW 132 million operating loss in the third quarter.

Third-quarter 2026 revenue fell 4.1% year on year.

Net income attributable to controlling shareholders went from KRW 266 million in the third quarter of 2025 to a KRW 923 million loss in the fourth quarter, a KRW 221 million loss in the first quarter of 2026, a KRW 689 million profit in the second quarter and a KRW 612 million loss in the third quarter.

The four quarters from the fourth quarter of 2025 through the third quarter of 2026 add up to a KRW 1.07 billion net loss attributable to controlling shareholders. Quarterly swings in profit are larger than swings in revenue, so whether profitable quarters can run in succession is the next thing to watch.

05

Industry analysis

The molecular diagnostics market in which Genematrix competes has shifted from COVID-19 testing toward non-COVID applications as testing has become routine.

Analysts note that Europe is adding or expanding reimbursement for multiplex tests, and that population aging and demand for personalized medicine are driving diagnostic technology development. This direction matches the infectious-disease multiplex panels the company is building for export.

Whether market growth translates into company revenue depends on country-by-country certification and local distribution results.

Most listed companies in the biopharma sector are focused on drugs and biologics, so their business models and revenue recognition differ from Genematrix's diagnostics model, and sector-average comparisons should be read with that gap in mind.

The company holds domestic COVID-19 and respiratory test approvals and has been adding European in-vitro diagnostic device listings. Its position is that of a domestic diagnostics company widening export markets on the back of overseas certifications.

06

Outlook

In its second-quarter 2026 results announcement on August 12, 2026, the company said it expects the profitable trend to continue, and it plans to expand exports through stronger overseas competitiveness and marketing and customer service tailored to each country's market.

Broadening export countries is another stated part of the plan. The memorandum with Zybio signed in April 2026 aims to build an integrated molecular diagnostics solution running from nucleic acid extraction through PCR analysis.

The two companies plan joint development of country-specific products and equipment-reagent optimization, but no launch timing has been disclosed. On the pipeline side, the hepatitis A vaccine candidate GMAI-02 moved into a Phase 1 trial agreement with Seoul National University Hospital in October 2026.

The Phase 1 study will enroll 30 healthy Korean adult men in a randomized, double-blind, active-controlled design, and it received Ministry of Food and Drug Safety approval for the trial plan.

In early September 2026, the project was selected for a government support program for domestic production of mandatory vaccines, securing development funds. The company says it will use Phase 1 data to advance follow-on clinical development.

Commercialization still requires clinical stages and marketing approval, so several steps remain. The points to watch are the safety and immunogenicity data from Phase 1 and the timing of Phase 2 entry.

07

Valuation

PER
—
PBR
1.5×
ROE
-6.0%
EPS
-₩53
BPS
₩869
Dividend per share
₩0

Because the company posted net losses attributable to controlling shareholders across the last four quarters, earnings-based multiples cannot be calculated. On a net asset basis, the price-to-book ratio sits above 1x, which means the shares trade at a premium to book value.

Total equity was KRW 17.5 billion at the end of 2025, and the controlling-shareholder portion is of the same size, so book value is clearly visible in the capital structure.

Continued losses erode that book value, and the rise in the debt-to-equity ratio from 31.9% in 2022 to 56.1% in 2025 is a change in financial capacity. No dividend is paid, so the valuation does not rest on dividend support.

The narrowing of annual operating losses since 2024 points to a direction of recovery in earnings power, but with a profitable quarter followed by a loss in the third quarter of 2026, the period is still short for judging valuation.

Comparisons with sector averages can rely only on revenue and book-value measures, since earnings-based metrics are not meaningful while losses persist.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Export growth and a profitable quarter

Second-quarter 2026 export sales reached KRW 1.22 billion, up 96% year on year, and operating profit of KRW 393 million turned the quarter positive. Sales of HPV tests rose 266% and STI tests 113%, showing growth across several export product lines. The company plans to widen its export countries. The 2025 operating loss also narrowed to KRW 679 million from 2024, pointing in the same direction.

Certifications and partnerships widening distribution

In June 2026 the TB/NTM detection kit received CE-IVDR listing, and in September 2025 the NeoPlex molecular panel and analysis software obtained the same certification. The April 2026 memorandum with Zybio adds a plan for an integrated solution running from extraction equipment through PCR analysis.

A growing base of European certifications supports expansion into more export countries. No launch date for the jointly developed products has been disclosed.

Vaccine pipeline with a domestic-supply goal

The hepatitis A vaccine candidate GMAI-02 entered a Phase 1 trial agreement with Seoul National University Hospital in October 2026 and received approval of its trial plan from the Ministry of Food and Drug Safety.

In early September 2026 it was selected for a government program supporting domestic production of mandatory vaccines, which secured development funding. The company expects the program to contribute to domestic supply of a vaccine now largely imported. Since the program is at an early Phase 1 stage, results are a long-term matter.

09

Bear factors

Swings in quarterly profit

The third quarter of 2026 posted an operating loss of KRW 132 million, revenue fell 4.1% year on year, and the quarter's loss came after a single profitable quarter in the second. The four quarters through the third quarter of 2026 add up to a KRW 1.07 billion net loss attributable to controlling shareholders.

Net income in the third quarter of 2026 was a loss of KRW 612 million, a swing from profit a year earlier. Until profitable quarters persist, the earnings structure cannot be considered stable.

Changes in the financial structure

The debt-to-equity ratio rose from 31.9% in 2022 to 56.1% in 2025. Operating cash flow was negative from 2022 through 2024 and turned positive only in 2025 at KRW 1.29 billion. Total equity stood at KRW 17.5 billion at the end of 2025, so continued losses reduce financial room. With about 20.39 million shares outstanding, the method of any future funding also bears on per-share dilution.

Small revenue base and an early-stage vaccine

Quarterly revenue has ranged from KRW 2.48 billion to KRW 2.91 billion since the third quarter of 2025, a small base. Export dependence above 40% of sales leaves the company exposed to changes in overseas policy and certifications.

The hepatitis A vaccine trial is designed for 30 participants, and Phase 2 entry depends on the results. Several stages remain before commercialization, so any contribution to revenue is far off.

10

Risk factors

Overseas dependence

More than 40% of sales come from NeoPlex exports, so certification requirements and policy changes in export countries affect revenue directly. The company plans to diversify export countries, but a blocked approval or distribution route in one market could move quarterly results sharply. Changes in the role split with local distribution partners also need monitoring.

Vaccine development risk

GMAI-02 is in Phase 1, and advancing to Phase 2 depends on safety and immunogenicity data. The Phase 1 design of 30 participants limits how far the results can be generalized. Revenue would require marketing approval and manufacturing, so development timelines and costs could extend.

Financial capacity and funding

The operating loss narrowed in 2025, but the third quarter of 2026 saw the loss widen again, and the debt-to-equity ratio reached 56.1%. Total equity of KRW 17.5 billion at the end of 2025 leaves less room if losses accumulate.

If additional funds are needed for development, dilution for existing shareholders and financial burden could both rise.

11

What to watch next

  1. March 31, 2027 (statutory deadline for the annual report)

    Confirm the full-year 2026 results and fourth-quarter profit in the annual report, and whether the second-quarter 2026 profitable turn carried through the year.

  2. May 15, 2027 (statutory deadline for the first-quarter 2027 report)

    Check whether first-quarter 2027 revenue and operating margin hold near the recent four-quarter range, and watch the change in export share.

  3. 2027 onward (timing not disclosed)

    Watch the safety and immunogenicity results of the GMAI-02 Phase 1 trial and whether Phase 2 begins, which indicates how quickly the program moves toward commercialization.

  4. Timing not disclosed

    Track the launch of the integrated molecular diagnostics solution co-developed with Zybio and its overseas distribution results, to see whether the partnership feeds into export sales.

12

Overall view

Genematrix is building its business around exports of the NeoPlex multiplex molecular diagnostics line, and second-quarter 2026 export sales rose 96% year on year. Annual operating loss narrowed from KRW 2.55 billion in 2023 to KRW 679 million in 2025, and operating cash flow turned positive in 2025.

Quarterly results, however, went from a profitable second quarter of 2026 back to a loss in the third quarter, and the four quarters through the third quarter of 2026 total a KRW 1.07 billion net loss attributable to controlling shareholders.

The debt-to-equity ratio rose from 31.9% in 2022 to 56.1% in 2025, so changes in financial capacity also need watching. The vaccine pipeline has entered Phase 1 with GMAI-02, but several stages remain before commercialization. Strengths include export growth, expanding certifications and a narrower annual loss.

Weaknesses include unstable quarterly profit, a weaker financial structure, a small revenue base and an early-stage vaccine. The next checkpoint is the fourth-quarter result and full-year operating margin in the 2026 annual report. This report does not offer an investment opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. view.asiae.co.kr
  2. comp.fnguide.com
  3. viva100.com
  4. vegannews.co.kr
  5. news.nate.com
  6. comp.wisereport.co.kr
  7. rapportian.com
  8. etoday.co.kr
  9. m.news.nate.com
  10. m.news.nate.com
  11. kr.investing.com
  12. news.nate.com
  13. m.news.nate.com
  14. newstap.co.kr
  15. newspim.com
  16. newsis.com
  17. jobkorea.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis